Autophagy Induction After Bortezomib for Myeloma
Multiple Myeloma

About this trial
This is an interventional treatment trial for Multiple Myeloma focused on measuring multiple myeloma, bortezomib, proteasome inhibitor
Eligibility Criteria
Inclusion Criteria:
- Histologically confirmed multiple myeloma (both newly diagnosed and relapsed patients are permitted)
- No more than one line of prior therapy containing bortezomib. No prior therapy with any other proteasome inhibitor.
- For subjects who received previous bortezomib, at least a partial response while on the bortezomib-containing therapy, without progression while on bortezomib-containing therapy or within 90 days of stopping bortezomib.
- Planned therapy, as determined by the patient's treating physician, with a bortezomib-containing regimen
- Medically suitable to undergo study procedures, including a one-week washout of prior therapy, one week of observation, and one week of single-agent bortezomib
- Provision of written informed consent
Exclusion Criteria
- Age <18 years (though the demographics of myeloma make it highly unlikely that any children will meet inclusion criteria)
- Treatment with other anti-myeloma agents, including corticosteroids, thalidomide, or lenalidomide, within the 7 days prior to the study baseline bone marrow biopsy.
- Inability to understand the informed consent document or unwillingness to consent.
- Written informed consent must be obtained from all patients before study entry.
Sites / Locations
- Abramson Cancer Center of the University of Pennsylvania
Arms of the Study
Arm 1
Experimental
Autophagy Induction After Bortezomib
Subjects will undergo a baseline bone marrow aspirate and biopsy (under sedation if preferred by the subject) and have baseline blood samples (and urine samples if clinically indicated for measurement of their myeloma). The following week, subjects will undergo a second bone marrow aspirate and biopsy and have additional blood samples taken for research assays prior to starting therapy on treatment day 1 with bortezomib at the standard dose of 1.3 mg/m2. Subjects will receive a second dose of bortezomib on treatment day 4, followed by a third bone marrow aspirate and biopsy on treatment day 4 or 5, along with serial blood samples on treatment days 4 and 5. After completion of the week of study treatment, subjects may continue treatment with the bortezomib-containing regimen planned by their treating oncologist. Active study participation will end after the completion of the week of study treatment.